Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment ...

MeiraGTx (MGTX) delivered earnings and revenue surprises of -24.00% and -89.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lilly will also gain exclusive access to MeiraGTx’s gene therapy platform technologies, including novel intravitreal capsids ...

As of September 30, 2025, MeiraGTx (MGTX) had cash and cash equivalents of approximately $14.8 million, as well as $2.8 million in receivables due ...

Reports Q3 revenue $410,000 vs. $10.9M last year. “Following the close of the third quarter, we are very pleased to have signed a strategic ...

Eli Lilly’s stock reached an all-time high of $1022.62 USD, marking a significant milestone for the pharmaceutical giant. According to InvestingPro data, the company’s RSI suggests the stock is in ...